Bcl-2 family proteins are essential for platelet survival
The DOI matches its Crossref record; 31 of the 32 references it cites were found in a registry or an index.
Abstract
Platelets are relatively short-lived, anucleated cells that are essential for proper hemostasis. The regulation of platelet survival in the circulation remains poorly understood. The process of platelet activation and senescence in vivo is associated with processes similar to those observed during apoptosis in nucleated cells, including loss of mitochondrial membrane potential, caspase activation, phosphatidylserine (PS) externalization, and cell shrinkage. ABT-737, a potent antagonist of Bcl-2, Bcl-X(L), and Bcl-w, induces apoptosis in nucleated cells dependent on these proteins for survival. In vivo, ABT-737 induces a reduction of circulating platelets that is maintained during drug therapy, followed by recovery to normal levels within several days after treatment cessation. Whole body scintography utilizing ([111])Indium-labeled platelets in dogs shows that ABT-737-induced platelet clearance is primarily mediated by the liver. In vitro, ABT-737 treatment leads to activation of key apoptotic processes including cytochrome c release, caspase-3 activation, and PS externalization in isolated platelets. Despite these changes, ABT-737 is ineffective in promoting platelet activation as measured by granule release markers and platelet aggregation. Taken together, these data suggest that ABT-737 induces an apoptosis-like response in platelets that is distinct from platelet activation and results in enhanced clearance in vivo by the reticuloendothelial system.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, targeting BCL-XL with conventional inhibitors causes severe thrombocytopenia, limiting their clinical use [5–7].”
From BCL-XL PROTAC degrader DT2216 synergizes with sotorasib in preclinical models of KRASG12C-mutated cancers (2022) · cites this paper as [6]
In the citing paper
“a potential clinical limitation of BCL-XLi is the fact that these inhibitors can cause on-target, reversible thrombocytopenia (Zhang et al., 2007).”
From A Landscape of Therapeutic Cooperativity in KRAS Mutant Cancers Reveals Principles for Controlling Tumor Evolution (2017) · cites this paper as Zhang et al., 2007
Citations
Cites
An inhibitor of Bcl-2 family proteins induces regression of solid tumours
Oltersdorf, T., Elmore, S. W., Shoemaker, A. R., Armstrong, R. C., Augeri, D. J., Belli, B. A., Bruncko, M., Deckwerth, T. L., Dinges, J., Hajduk, P. J., et al. (2005) · Nature · doi:10.1038/nature03579 · Cited by 3,416 · cited 2×
“ABT-737 is a small molecule antagonist of the prosurvival Bcl-2 family proteins Bcl-XL, Bcl-2, and Bcl-w that induces apoptosis in tumor cells in a mitochondria-dependent fashion.(18) Treatment of ABT-737 in dogs leads to a rapid, dosedependent decrease in circulating platelets that return to baseline within 72-h post…”
BackgroundSelf-citationA receptor for phosphatidylserine-specific clearance of apoptotic cells
Fadok, V. A., Bratton, D. L., Rose, D. M., Pearson, A., Ezekewitz, R. A. B., & Henson, P. M. (2000) · Nature · doi:10.1038/35011084 · Cited by 1,491 · cited 1×
“PS externalization on cells has also been shown to signal the specific engulfment of these unwanted cells by phagocytes leading to clearance from the circulation .(9,15,25) Finally, the fact that the enantiomer negative control does not activate the apoptotic cascade at equivalent concentrations supports the notion th…”
BackgroundThe biogenesis of platelets from megakaryocyte proplatelets
Patel, S. R. (2005) · Journal of Clinical Investigation · doi:10.1172/jci26891 · Cited by 603 · cited 1×
“The similarities between platelet biogenesis from megakaryocytes and apoptosis include membrane blebbing, membrane condensation, DNA fragmentation, cell shrinkage, and ultimately the formation of apoptotic bodies.(5,6) The consequence of this apoptotic process is that each mature megakaryocyte fragments into thousands…”
BackgroundThe platelet release reaction: granules' constituents, secretion and functions
Rendu, F., & Brohard-Bohn, B. (2001) · Platelets · doi:10.1080/09537100120068170 · Cited by 599 · cited 4×
“Upon platelet activation, a series of granules are released that are essential for the full activation response.(21) To further investigate other direct effects of ABT-737 on platelet dynamics, isolated platelets were treated with ABT-737 and classical markers of granule release were monitored.”
BackgroundMethodInfluentialProgrammed cell death and Bcl-2 protection in the absence of a nucleus.
Jacobson, M. D., Burne, J. F., & Raff, M. C. (1994) · The EMBO Journal · doi:10.1002/j.1460-2075.1994.tb06459.x · Cited by 552 · cited 1×
“Previous studies have shown that apoptotic agents promote morphological changes in anucleated cytoplast that resemble characteristics of programmed cell death.(23,24) In platelets, the morphological changes of apoptosis closely resemble those of activation, including PS externalization, microparticle release (i.”
BackgroundMartin, S. J., Finucane, D. M., Amarante-Mendes, G. P., O'Brien, G. A., & Green, D. R. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.46.28753 · Cited by 372 · cited 1×
“Previous studies have shown that apoptotic agents promote morphological changes in anucleated cytoplast that resemble characteristics of programmed cell death.(23,24) In platelets, the morphological changes of apoptosis closely resemble those of activation, including PS externalization, microparticle release (i.”
BackgroundWolf, B. B., Goldstein, J. C., Stennicke, H. R., Beere, H., Amarante-Mendes, G. P., Salvesen, G. S., & Green, D. R. (1999) · Blood · doi:10.1182/blood.v94.5.1683 · Cited by 323
The role of the Bcl-2 protein family in cancer
Coultas, L., & Strasser, A. (2003) · Seminars in Cancer Biology · doi:10.1016/s1044-579x(02)00129-3 · Cited by 242 · cited 1×
“The process of apoptosis can be viewed as a cascade of events initiating from the accumulation of a death signal(s), release of apoptotic factors from the mitochondria, activation of initiator/effector caspases, ultimately leading to cell death.(16) Our studies demonstrate that ABT-737 initiates the apoptotic cascade…”
BackgroundA Simple Nonradioisotope Technic for the Determination of Platelet Life-Span
Stuart, M. J., Murphy, S., & Oski, F. A. (1975) · New England Journal of Medicine · doi:10.1056/nejm197506192922502 · Cited by 242 · cited 1×
“released into the circulation, platelets rapidly age with a halflife of 4–5 days.(7,8) As platelets age, they lose their ability to function and are subsequently removed from circulation.”
BackgroundRole of platelets in thrombosis and hemostasis
Packham, M. A. (1994) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/y94-043 · Cited by 215 · cited 2×
“Subsequent platelet activation, granule release, and aggregation are essential for the formation of a hemostatic plug that limits blood loss and stimulates repair.(2) There are several morphological changes associated with platelet activation that are reminiscent of nucleated cell apoptosis.”
Background
Cited by
Items 101–200 of 452
Kodama, T., Takehara, T., Hikita, H., Shimizu, S., Shigekawa, M., Li, W., Miyagi, T., Hosui, A., Tatsumi, T., Ishida, H., et al. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.195370 · Cited by 84
Zhang, X., Thummuri, D., He, Y., Liu, X., Zhang, P., Zhou, D., & Zheng, G. (2019) · Chemical Communications · doi:10.1039/c9cc07217a · Cited by 86
Whitecross, K. F., Alsop, A. E., Cluse, L. A., Wiegmans, A., Banks, K.-M., Coomans, C., Peart, M. J., Newbold, A., Lindemann, R. K., & Johnstone, R. W. (2009) · Blood · doi:10.1182/blood-2008-05-156851 · Cited by 81
“Accordingly, diseases such as follicular lymphoma, which develops as a result of deregulated expression pf Bcl-2 caused by a t(14;18) chromosomal translocation, will be prime candidates for single agent therapy with ABT-737.”
BackgroundSTIM and Orai in platelet function
Varga-Szabó, D., Braun, A., & Nieswandt, B. (2011) · Cell Calcium · doi:10.1016/j.ceca.2011.04.002 · Cited by 82
Anderson, G. R., Winter, P. S., Lin, K. H., Nussbaum, D. P., Cakir, M., Stein, E. M., Soderquist, R. S., Crawford, L., Leeds, J. C., Newcomb, R., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.07.006 · Cited by 80
“Finally, a potential clinical limitation of BCL-XLi is the fact that these inhibitors can cause on-target, reversible thrombocytopenia (Zhang et al., 2007).”
BackgroundPhillips, D. C., Jin, S. S., Gregory, G. P., Zhang, Q., Xue, J., Zhao, X., Chen, J., Tong, Y., Zhang, H., Smith, M. L., et al. (2019) · Leukemia · doi:10.1038/s41375-019-0652-0 · Cited by 81
Self-citationKeuling, A. M., Felton, K. E. A., Parker, A., Akbari, M., Andrew, S. E., & Tron, V. A. (2009) · PLoS ONE · doi:10.1371/journal.pone.0006651 · Cited by 80
Cell death response to anti-mitotic drug treatment in cell culture, mouse tumor model and the clinic
Shi, J., & Mitchison, T. J. (2017) · Endocrine-Related Cancer · doi:10.1530/erc-17-0003 · Cited by 79
“A major challenge to clinical development of Navitoclax is that Bcl-xL inhibition tends to kill platelets, whose lifespan is naturally limited by apoptosis (Zhang et al. 2007).”
The role of the intrinsic apoptosis pathway in platelet life and death
Kile, B. T. (2009) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2009.03366.x · Cited by 90
Elkholi, R., Renault, T. T., Serasinghe, M. N., & Chipuk, J. E. (2014) · Cancer & Metabolism · doi:10.1186/2049-3002-2-16 · Cited by 88
“rely exclusively on BCL-xL for survival [100,101].”
White, M. J., Schoenwaelder, S. M., Josefsson, E. C., Jarman, K. E., Henley, K. J., James, C., Debrincat, M. A., Jackson, S. P., Huang, D. C. S., & Kile, B. T. (2012) · Blood · doi:10.1182/blood-2011-11-394858 · Cited by 82
Discovery of a potent and selective Bcl-2 inhibitor using SAR by NMR
Petros, A. M., Huth, J. R., Oost, T. K., Park, C., Ding, H., Wang, X., Zhang, H., Nimmer, P. M., Mendoza, R. R., Sun, C. C., et al. (2010) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2010.09.033 · Cited by 81
Self-citationPaik, P. K., Rudin, C. M., Brown, A. B., Rizvi, N. A., Takebe, N., Travis, W. D., James, L. P., Ginsberg, M. S., Juergens, R. A., Markus, S., et al. (2010) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-010-1265-5 · Cited by 81
“Recent studies have highlighted Bcl-XL’s role in protecting platelets from apoptosis, which is underscored by the rapid though reversible induction of thrombocytopenia in mice and dogs treated with ABT-737 [21, 22].”
BackgroundBalachander, S. B., Criscione, S. W., Byth, K. F., Cidado, J. R., Adam, A., Lewis, P. M., Macintyre, T., Wen, S., Lawson, D., Burke, K. A., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-0863 · Cited by 76
“At doses leading to complete tumor regression, AZD4320 causes only transient thrombocytopenia Thrombocytopenia has previously been reported as a consequence of inhibition or depletion of Bcl-xL in platelets, resulting in accelerated platelet clearance (38, 39).”
BackgroundTreatment of drug-induced immune thrombocytopenias
Marini, I., Uzun, G., Jamal, K., & Bakchoul, T. (2022) · Haematologica · doi:10.3324/haematol.2021.279484 · Cited by 76
Bacteria differentially induce degradation of Bcl-xL, a survival protein, by human platelets
Kraemer, B. F., Campbell, R. A., Schwertz, H., Franks, Z. G., Vieira de Abreu, A., Grundler, K., Kile, B. T., Dhakal, B. K., Rondina, M. T., Kahr, W. H. A., et al. (2012) · Blood · doi:10.1182/blood-2012-04-420661 · Cited by 69
Cancer cell death: Cell-autonomous and immunogenic dimensions
Galluzzi, L., Kepp, O., Zitvogel, L., Tang, D., & Kroemer, G. (2025) · Cancer Cell · doi:10.1016/j.ccell.2025.12.005 · Cited by 77
Platelet senescence and phosphatidylserine exposure
Dasgupta, S. K., Argaiz, E. R., Mercado, J. E. C., Maul, H. O. E., Garza, J., Enríquez, A. B., Abdel‐Monem, H., Prakasam, A., Andreeff, M., & Thiagarajan, P. (2010) · Transfusion · doi:10.1111/j.1537-2995.2010.02676.x · Cited by 76
Human antibody-based chemically induced dimerizers for cell therapeutic applications
Hill, Z. B., Martinko, A. J., Nguyen, D., & Wells, J. A. (2017) · Nature Chemical Biology · doi:10.1038/nchembio.2529 · Cited by 78
“40 Additionally, others have also shown that ABT-737 can be applied to activate engineered proteins in live-cell experiments with little observed cytotoxicity.”
Discovery of IAP-recruiting BCL-XL PROTACs as potent degraders across multiple cancer cell lines
Zhang, X., He, Y., Zhang, P., Budamagunta, V., Lv, D., Thummuri, D., Yang, Y., Pei, J., Yuan, Y., Zhou, D., et al. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112397 · Cited by 71
“This is because BCL- XL is required for the viability of platelets [8, 9].”
BackgroundExpansion of the neonatal platelet mass is achieved via an extension of platelet lifespan
Liu, Z.-J., Hoffmeister, K. M., Hu, Z., Mager, D. E., Ait-Oudhia, S., Debrincat, M. A., Pleines, I., Josefsson, E. C., Kile, B. T., Italiano, J., et al. (2014) · Blood · doi:10.1182/blood-2013-06-508200 · Cited by 68
“incubation with ABT-737 for 2 hours induced platelet apoptosis in a dose-dependent manner.(8,9,28) Compared with adult platelets, neonatal platelets were less sensitive to ABT-737 at concentrations $30 nM (P , .”
The glycoprotein Ibα–von Willebrand factor interaction induces platelet apoptosis
Li, S., Wang, Z., LIAO, Y., ZHANG, W., Shi, Q. F., YAN, R., RUAN, C., & Dai, K. (2009) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2009.03653.x · Cited by 73
Kelly, P. N., White, M. J., Goschnick, M. W., Fairfax, K. A., Tarlinton, D. M., Kinkel, S. A., Bouillet, P., Adams, J. M., Kile, B. T., & Strasser, A. (2010) · Cell Death & Differentiation · doi:10.1038/cdd.2010.43 · Cited by 68
“Platelets depend on Bcl-xL to restrain Bak and maintain viability in the circulation.(31,58) Loss of function mutations in Bcl-xL cause dose-dependent reductions in platelet life-span(31) and pharmacological inhibition of Bcl-xL with the BH3-mimetic ABT-737 59 triggers platelet apoptosis and thrombocytopenia, apparent…”
BackgroundMechanisms of venetoclax resistance and solutions
Liu, J., Chen, Y., Yu, L., & Yang, L. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1005659 · Cited by 76
“However, their clinical application is hampered by the toxicity associated with multitarget drugs: navitoclax causes thrombocytopenia in patients before an effective dose is reached (NCT00406809) (4, 5) because its target BCL-2 and BCL-XL, especially the latter, play an important role in platelet survival (6, 7).”
BackgroundJosefsson, E. C., Vainchenker, W., & James, C. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21207591 · Cited by 68
“While Bcl-w has been shown to be present in platelets [20,28], it is not likely to control platelet life span since systemic BCL2L2 knockout mice did not alter platelet numbers [35,36].”
BackgroundInfluentialAntiplatelet antibody predicts platelet desialylation and apoptosis in immune thrombocytopenia
Zheng, S. S., Ahmadi, Z., Leung, H. H. L., Wong, R., Feng, Y., Perdomo, J., & Chong, B. H. (2022) · Haematologica · doi:10.3324/haematol.2021.279751 · Cited by 68
Blood platelets and inflammation: Their relationship with liver and digestive diseases
Ripoche, J. (2011) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2011.02.012 · Cited by 76
Ko, T. K., Chuah, C. T. H., Huang, J. W. J., Ng, K.-P., & Ong, S. T. (2014) · Oncotarget · doi:10.18632/oncotarget.1925 · Cited by 71
“This is due to the inhibitory effect of ABT-263 on BCL-XL, which is pivotal for platelet survival [13, 14].”
BackgroundMicroRNA dysregulation to identify therapeutic target combinations for chronic lymphocytic leukemia
Rassenti, L. Z., Balatti, V., Ghia, E. M., Palamarchuk, A., Tomasello, L., Fadda, P., Pekarsky, Y., Widhopf, G. F., Kipps, T. J., & Croce, C. M. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1708264114 · Cited by 71
“This inhibitor, however, also targeted other members of the Blc2 family, including BclXL, which is essential for platelet survival (9, 10).”
BackgroundDiscovery of Potent and Selective Benzothiazole Hydrazone Inhibitors of Bcl-XL
Sleebs, B. E., Kersten, W. J. A., Kulasegaram, S., Nikolakopoulos, G., Hatzis, E., Moss, R. M., Parisot, J. P., Yang, H. J., Czabotar, P. E., Fairlie, W. D., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400556w · Cited by 72
Novel mechanisms of platelet clearance and thrombopoietin regulation
Grozovsky, R., Giannini, S., Falet, H., & Hoffmeister, K. M. (2015) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000170 · Cited by 66
Li, C., Xing, G., Dong, M., Li, Z., Li, J., Wang, G., Zou, D.-J., Wang, R., Liu, J., & Niu, Y. (2010) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2010.03.013 · Cited by 69
Senolytic targets and new strategies for clearing senescent cells
Ge, M., Hu, L., Ao, H.-S., Zi, M., Kong, Q., & He, Y. (2021) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2021.111468 · Cited by 67
Caloric restriction modulates Mcl-1 expression and sensitizes lymphomas to BH3 mimetic in mice
Meynet, O., Zunino, B., Happo, L., Pradelli, L. A., Chiche, J., Jacquin, M. A., Mondragón, L., Tanti, J., Taillan, B., Garnier, G., et al. (2013) · Blood · doi:10.1182/blood-2013-01-478651 · Cited by 70
“We confirmed that the ABT-737 treatment was active because it induced thrombocytopenia (Figure 2B), as previously described.(32) The degree of thrombocytopenia was not different between the ABT-737 and CR 1 ABT-737 groups (Figure 2B), consistent with Mcl-1 levels not having an impact on platelet survival.”
ResultProteome and functional decline as platelets age in the circulation
Allan, H. E., Hayman, M. A., Marcone, S., Chan, M. V., Edin, M. L., Maffucci, T., Joshi, A., Menke, L., Crescente, M., Mayr, M., et al. (2021) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.15496 · Cited by 64
Molecular Cell Biology of Apoptosis and Necroptosis in Cancer
Dillon, C. P., & Green, D. R. (2016) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-39406-0_1 · Cited by 66
Therapeutics targeting Bcl-2 in hematological malignancies
Ruefli-Brasse, A. A., & Reed, J. C. (2017) · Biochemical Journal · doi:10.1042/bcj20170080 · Cited by 66
Anti-cancer drug discovery and development: Bcl-2 family small molecule inhibitors
Liu, Q., & Wang, H. (2012) · Communicative & Integrative Biology · doi:10.4161/cib.21554 · Cited by 67
Bate-Eya, L. T., den Hartog, I. J. M., van der Ploeg, I., Schild, L. G., Köster, J., Santo, E. E., Westerhout, E. M., Versteeg, R., Caron, H. N., Molenaar, J. J., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.8547 · Cited by 67
Khan, S., Wiegand, J., Zhang, P., Hu, W., Thummuri, D., Budamagunta, V., Hua, N., Jin, L., Allegra, C. J., Kopetz, S. E., et al. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01241-3 · Cited by 62
Polier, G., Giaisi, M., Köhler, R., Müller, W. W., Lutz, C., Buss, E. C., Krammer, P. H., & Li‐Weber, M. (2014) · International Journal of Cancer · doi:10.1002/ijc.29009 · Cited by 66
“Inhibition of Bcl-xL by ABT-263 or ABT-737 was shown to induce a rapid, concentration-dependent decrease in the number of circulating platelets after the first dose.(9,47) Although the reduction of platelets by the first dose of ABT-737 or ABT-263 administration is reversible and holds steady for the remaining doses,(…”
BackgroundDiscovery of a Novel BCL-XL PROTAC Degrader with Enhanced BCL-2 Inhibition
Pal, P., Thummuri, D., Lv, D., Liu, X., Zhang, P., Hu, W., Poddar, S. K., Hua, N., Khan, S., Yuan, Y., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00517 · Cited by 60
Richard, D. J., Lena, R., Bannister, T., Blake, N., Pierceall, W. E., Carlson, N. E., Keller, C. E., Koenig, M., He, Y., Minond, D., et al. (2013) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2013.08.017 · Cited by 59
Schmid, D., Jarvis, G. E., Fay, F., Small, D. M., Greene, M. K., Majkut, J., Spence, S., McLaughlin, K. M., McCloskey, K. D., Johnston, P. G., et al. (2014) · Cell Death & Disease · doi:10.1038/cddis.2014.413 · Cited by 56
“maintaining elevated levels of Bcl-X(L), the inhibition of which by ABT-263/ABT-737 results in premature initiation of platelet apoptosis.(8,9) In spite of these issues, ABT-263 is still under”
BackgroundRegulatory Role of Proteasome in Determination of Platelet Life Span
Nayak, M. K., Kulkarni, P. P., & Dash, D. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.403154 · Cited by 57
“Platelets abundantly express Bax (39) as well as the Bax-specific mRNA (40).”
BackgroundThe application of BH3 mimetics in myeloid leukemias
Parry, N., Wheadon, H., & Copland, M. (2021) · Cell Death and Disease · doi:10.1038/s41419-021-03500-6 · Cited by 60
Targeted Therapy Development in Acute Myeloid Leukemia
Totiger, T. M., Ghoshal, A., Zabroski, J., Sondhi, A. K., Bucha, S., Jahn, J., Feng, Y., & Taylor, J. (2023) · Biomedicines · doi:10.3390/biomedicines11020641 · Cited by 60
“Hence, the other BCL-2 inhibitors came into existence to fill this gap [54,55].”
BackgroundBcl-2 Modulation to Activate Apoptosis in Prostate Cancer
Bray, K., Chen, H., Karp, C. M., May, M., Ganesan, S., Karantza‐Wadsworth, V., DiPaola, R. S., & White, E. P. (2009) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-09-0166 · Cited by 60
“ABT-737 as a single agent is insufficient to induce apoptosis in most cancer cell lines and xenografts (15, 37) as well as in normal tissues with the exception of platelets, which are particularly reliant on Bcl-xL for survival (40, 41).”
BackgroundChoo, H. J., Kholmukhamedov, A., Zhou, C., & Jobe, S. M. (2017) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.117.309473 · Cited by 56
“Treatment of platelets with a BcL-xL inhibitor, such as ABT-737, also results in phosphatidylserine externalization.(2,13) Inhibition of BcL-xL results in Bax/Bak-mediated caspase activation, phosphatidylserine externalization, and in vivo platelet clearance.”
JAKs to STATs: A tantalizing therapeutic target in acute myeloid leukemia
Venugopal, S., Bar‐Natan, M., & Mascarenhas, J. O. (2019) · Blood Reviews · doi:10.1016/j.blre.2019.100634 · Cited by 56
Senolytic Targeting of Bcl-2 Anti-Apoptotic Family Increases Cell Death in Irradiated Sarcoma Cells
Lafontaine, J., Cardin, G. B., Malaquin, N., Boisvert, J.-S., Rodier, F., & Wong, P. (2021) · Cancers · doi:10.3390/cancers13030386 · Cited by 54
“The thrombocytopenia associated with ABT-263 is linked to BCL-XL inhibition [63] and can be avoided with ABT-199 which is specific to BCL2 [50,64].”
BackgroundAging and Mesenchymal Stem Cells: Therapeutic Opportunities and Challenges in the Older Group
Chen, H., Liu, O., Chen, S., & Zhou, Y. (2021) · Gerontology · doi:10.1159/000516668 · Cited by 57
Josefsson, E. C., Ramström, S., Thaler, J., Lordkipanidzé, M., Agbani, E. O., Alberio, L., Bakchoul, T., Bouchard, B. A., Camera, M., Chen, V. M. Y., et al. (2023) · Journal of Thrombosis and Haemostasis · doi:10.1016/j.jtha.2023.05.001 · Cited by 53
miR-326 Targets Antiapoptotic Bcl-xL and Mediates Apoptosis in Human Platelets
Yu, S., Huang, H., Deng, G., Xie, Z., Ye, Y., Guo, R., Cai, X., Hong, J., Qian, D., Zhou, X., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0122784 · Cited by 53
“Studies show that the intrinsic pathway regulates the lifespan of platelets [3,4,6].”
BackgroundThiagarajan, P., & Afshar‐Kharghan, V. (2013) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2013.03.004 · Cited by 57
Valentini, E., D’Aguanno, S., Martile, M. D., Montesano, C., Ferraresi, V., Patsilinakos, A., Sabatino, M., Antonini, L., Chiacchiarini, M., Valente, S., et al. (2022) · Theranostics · doi:10.7150/thno.64233 · Cited by 54
“conceivable that the use of Bcl-2 family inhibitors, in combination with other drugs, could allow the use of lower doses of both drugs employed in the combination, with consequent less toxicity and reduction of trombocytopenia, which is frequently associated with ABT-263 treatment [23, 24].”
1,2,3,4-Tetrahydroisoquinoline (THIQ) as privileged scaffold for anticancer de novo drug design
Faheem, F., Kumar, B. K., Sekhar, K. V. G. C., Chander, S., Kunjiappan, S., & Murugesan, S. (2021) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2021.1916464 · Cited by 55
“necessary for the survival of B and T lymphocytes [148], while platelet survival depends upon BCL-XL [149].”
BackgroundBeurlet, S., Omidvar, N., Gorombei, P., Krief, P., Pogam, C. L., Setterblad, N., de la Grange, P., Lebœuf, C., Janin, A., Noguera, M., et al. (2013) · Blood · doi:10.1182/blood-2012-07-445635 · Cited by 57
“The blood counts show that the platelets and lymphocytes are not rescued due to the reported toxicity of the drug as it targets BCL-xL.(30,35) However, the other blood parameters, such as neutrophil count and white blood cell counts are rescued.”
BackgroundResultChiappori, A., Schreeder, M. T., Moezi, M. M., Stephenson, J., Blakely, J., Salgia, R., Chu, Q. S.-C., Ross, H. J., Subramaniam, D. S., Schnyder, J., et al. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.21 · Cited by 53
Physiological restraint of Bak by Bcl-x L is essential for cell survival
Lee, E. F., Grabow, S., Chappaz, S., Dewson, G., Hockings, C., Kluck, R. M., Debrincat, M. A., Gray, D. H. D., Witkowski, M. T., Evangelista, M., et al. (2016) · Genes & Development · doi:10.1101/gad.279414.116 · Cited by 57
Cookson, P., Sutherland, J., Turner, C., Bashir, S., Wiltshire, M., Hancock, V., Smith, K., & Cardigan, R. A. (2010) · Transfusion Medicine · doi:10.1111/j.1365-3148.2010.01034.x · Cited by 49
“Recent studies have shown that canine and murine and platelets can undergo Bcl-xL and mitochondrial-mediated apoptosis, an irreversible programme of controlled cell death (Mason et al., 2007; Zhang et al., 2007).”
BackgroundRahman, S. F. A., Muniandy, K., Soo, Y. K., Tiew, E. Y. H., Tan, K. X., Bates, T. E., & Mohana‐Kumaran, N. (2020) · Biochemistry and Biophysics Reports · doi:10.1016/j.bbrep.2020.100756 · Cited by 57
“However, co-targeting BCL-XL and MCL-1 may pose an issue in the clinic, as inhibition of BCL-XL may result in thrombocytopenia [6,7].”
BackgroundKhan, S., Kellish, P., Connis, N., Thummuri, D., Wiegand, J., Zhang, P., Zhang, X., Budamagunta, V., Hua, N., Yang, Y., et al. (2023) · Cell Death Discovery · doi:10.1038/s41420-022-01296-8 · Cited by 43
“Given that BCL-XL inhibitors including navitoclax cause thrombocytopenia, a combination of navitoclax with AZD8055 (or another mTOR inhibitor) may not be clinically feasible [14, 15].”
BackgroundThe path to venetoclax resistance is paved with mutations, metabolism, and more
Sullivan, G. P., Flanagan, L., Rodrigues, D. A., & Chonghaile, T. N. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abo6891 · Cited by 50
Selective triggering of platelet apoptosis, platelet activation or both
Gyulkhandanyan, A. V., Mutlu, A., Freedman, J. J., & Leytin, V. (2013) · British Journal of Haematology · doi:10.1111/bjh.12237 · Cited by 51
“Platelet apoptotic and/or activation events were determined in five platelet groups treated with: (i) diluent buffer A, (ii) diluent buffer B, (iii) 1 U/ml thrombin (Leytin et al, 2000a, 2006a), (iv) 30 lmol/l ABT-737 (Zhang et al, 2007) and (v) 10 lmol/l A23187 (Leytin et al, 2009).”
BackgroundMethodResultInfluentialRukoyatkina, N., Викторович, М. И., Walter, U., & Gambaryan, S. P. (2013) · Cell Death and Disease · doi:10.1038/cddis.2013.459 · Cited by 47
Rosa, N., Speelman-Rooms, F., Parys, J. B., & Bultynck, G. (2022) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2022.188791 · Cited by 51
Scatizzi, J. C., Hutcheson, J., Pope, R. M., Firestein, G. S., Koch, A. E., Mavers, M., Smason, A., Agrawal, H., Haines, G. K., Chandel, N. S., et al. (2010) · Arthritis & Rheumatism · doi:10.1002/art.27198 · Cited by 46
Drugs and Clinical Approaches Targeting the Antiapoptotic Protein: A Review
Han, Z., Liang, J., Li, Y., & He, J. (2019) · BioMed Research International · doi:10.1155/2019/1212369 · Cited by 46
“suggested that Bcl-xL is crucial for the survival of mature platelets in vivo, so the previous two applications are not suitable drugs for patients [36].”
BackgroundRegulation of platelet membrane protein shedding in health and disease
Au, A. E., & Josefsson, E. C. (2016) · Platelets · doi:10.1080/09537104.2016.1203401 · Cited by 45
Platelet hyperactivation, apoptosis and hypercoagulability in patients with acute pulmonary embolism
Rezania, S., Puskarich, M. A., Petrusca, D. N., Neto‐Neves, E. M., Rondina, M. T., & Kline, J. A. (2017) · Thrombosis Research · doi:10.1016/j.thromres.2017.05.009 · Cited by 44
Wakui, N., Yoshino, R., Yasuo, N., Ohue, M., & Sekijima, M. (2017) · Journal of Molecular Graphics and Modelling · doi:10.1016/j.jmgm.2017.11.011 · Cited by 47
Delaney, M. K., Liu, J., Kim, K., Shen, B., Stojanovic‐Terpo, A., Zheng, Y., Cho, J., & Du, X. (2014) · Blood · doi:10.1182/blood-2014-03-560821 · Cited by 44
Apoptotic Processes in Megakaryocytes and Platelets
White, M. J., & Kile, B. T. (2010) · Seminars in Hematology · doi:10.1053/j.seminhematol.2010.03.006 · Cited by 46
Challenges and Advances in Managing Thrombocytopenic Cancer Patients
Leader, A., Hofstetter, L., & Spectre, G. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10061169 · Cited by 44
A guide to senolytic intervention in neurodegenerative disease
Lee, S., Wang, E. Y., Steinberg, A. B., Walton, C. C., Chinta, S. J., & Andersen, J. K. (2021) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2021.111585 · Cited by 39
Exploiting mitochondrial apoptosis for the treatment of cancer
Fulda, S. (2010) · Mitochondrion · doi:10.1016/j.mito.2010.05.001 · Cited by 45
Combination with vorinostat overcomes ABT-263 (navitoclax) resistance of small cell lung cancer
Nakajima, W., Sharma, K., Hicks, M. A., Le, N., Brown, R., Krystal, G. W., & Harada, H. (2016) · Cancer Biology & Therapy · doi:10.1080/15384047.2015.1108485 · Cited by 41
Infection with flaviviruses requires BCLXL for cell survival
Suzuki, T., Okamoto, T., Katoh, H., Sugiyama, Y., Kusakabe, S., Tokunaga, M., Hirano, J., Miyata, Y., Fukuhara, T., Ikawa, M., et al. (2018) · PLoS Pathogens · doi:10.1371/journal.ppat.1007299 · Cited by 44
“Treatment with inhibitors of BCLX such as ABT-263 was demonstrated to cause thrombocytopenia due to their neutralization of BCLXL in circulating platelets without bone marrow toxicity [30,63,64].”
BackgroundMitchell, W. B., Pinheiro, M. D. O., Boulad, N., Kaplan, D. R., Edison, M. N., Psaila, B., Karpoff, M. N., White, M. J., Josefsson, E. C., Kile, B. T., et al. (2014) · American Journal of Hematology · doi:10.1002/ajh.23832 · Cited by 43
“Pharmacological inhibition of Bcl-xL with the BH3 mimetic drugs such as ABT-737 [9] or ABT-263 (Navitoclax) [10] triggers platelet death [6,11–14] and thrombocytopenia in mice [6,15], dogs [14], and humans [16,17].”
BackgroundCell death in hematological tumors
Fulda, S. (2009) · APOPTOSIS · doi:10.1007/s10495-008-0306-6 · Cited by 51
Selective inhibitors of Bcl-2 and Bcl-xL: Balancing antitumor activity with on-target toxicity
Hennessy, E. J. (2016) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2016.03.032 · Cited by 44
Antiplatelet Agents Inhibit the Generation of Platelet-Derived Microparticles
Giacomazzi, A., Degan, M., Calabria, S., Meneguzzi, A., & Minuz, P. (2016) · Frontiers in Pharmacology · doi:10.3389/fphar.2016.00314 · Cited by 41
“On the other hand, microvesiculation by apoptotic platelets results from a disruption of the balance between Bcl survival and Bak apoptotic signals (Mason et al., 2007; Zhang et al., 2007; Schoenwaelder et al., 2009), independently of platelet activation (Zhang et al., 2013).”
BackgroundLejman, M., Kuśmierczuk, K., Bednarz, K., Ostapińska, K., & Zawitkowska, J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22189827 · Cited by 45
Platelet Life Span and Apoptosis
Josefsson, E. C., White, M. J., Dowling, M. R., & Kile, B. T. (2011) · Methods in molecular biology · doi:10.1007/978-1-61779-307-3_5 · Cited by 41
Targeting Anti-Apoptotic BCL-2 Family Proteins for Cancer Treatment
Zhang, X., Liu, X., Zhou, D., & Zheng, G. (2020) · Future Medicinal Chemistry · doi:10.4155/fmc-2020-0004 · Cited by 43
Mutlu, A., Gyulkhandanyan, A. V., Freedman, J. J., & Leytin, V. (2012) · British Journal of Haematology · doi:10.1111/bjh.12066 · Cited by 46
“Therefore in this study we initiated platelet apoptosis through the intrinsic pathway, using the BH3-only mimetic ABT-737 and calcium ionophore A23187, agents that trigger the mitochondrial platelet apoptosis (Mason et al, 2007; Zhang et al, 2007; Leytin et al, 2009a).”
BackgroundMethodInfluentialLeverson, J. D., & Cojocari, D. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00458 · Cited by 43
Venetoclax for the treatment of multiple myeloma
Vaxman, I., Sidiqi, M. H., & Gertz, M. A. (2018) · Expert Review of Hematology · doi:10.1080/17474086.2018.1548931 · Cited by 40
Mu, H., Zhu, X., Jia, H., Zhou, L., & Liu, H. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.643382 · Cited by 43
Structure-Guided Rescaffolding of Selective Antagonists of BCL-XL
Koehler, M. F. T., Bergeron, P., Choo, E. F., Lau, K., Ndubaku, C., Dudley, D., Gibbons, P., Sleebs, B. E., Rye, C. S., Nikolakopoulos, G., et al. (2014) · ACS Medicinal Chemistry Letters · doi:10.1021/ml500030p · Cited by 38
Self-citationSelect Bcl-2 antagonism restores chemotherapy sensitivity in high-risk neuroblastoma
Tanos, R., Karmali, D., Nalluri, S., & Goldsmith, K. C. (2016) · BMC Cancer · doi:10.1186/s12885-016-2129-0 · Cited by 42
“This dose limiting toxicity of Navitoclax is caused by its Bcl-XL -targeting properties as mature circulating platelets depend on Bcl-XL for survival [11, 12].”
BackgroundPleines, I., Lebois, M., Gangatirkar, P., Au, A. E., Lane, R. M., Henley, K. J., Kauppi, M., Corbin, J. E., Cannon, P., Bernardini, J. P., et al. (2018) · Blood · doi:10.1182/blood-2017-11-816355 · Cited by 40
Neutralization of BCL-2/XL Enhances the Cytotoxicity of T-DM1 In Vivo
Zoeller, J. J., Vagodny, A., Taneja, K. L., Tan, B. Y., O’Brien, N. A., Slamon, D. J., Sampath, D., Leverson, J. D., Bronson, R. T., Dillon, D. A. R., et al. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-0743 · Cited by 41
“ABT-263 treatment depletes mature platelets due to the dependence of these cells on BCL-XL for survival (63, 64).”
BackgroundSingle and dual target inhibitors based on Bcl-2: Promising anti-tumor agents for cancer therapy
Liu, T., Wu, Z., He, Y., Xiao, Y., & Xia, C. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112446 · Cited by 41
Gangat, N., & Tefferi, A. (2020) · Blood Cancer Journal · doi:10.1038/s41408-020-00388-x · Cited by 40
Bcl‐2 proteins in development, health, and disease of the hematopoietic system
Kollek, M., Müller, A., Egle, A., & Erlacher, M. (2016) · FEBS Journal · doi:10.1111/febs.13683 · Cited by 42
The chemical biology of apoptosis: Revisited after 17 years
Yang, S., Mao, Y., Zhang, H., Xu, Y., An, J., & Huang, Z. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.05.019 · Cited by 40
Self-citationPotent and Specific Peptide Inhibitors of Human Pro-Survival Protein Bcl-xL
Dutta, S., Ryan, J. A., Chen, T. S., Kougentakis, C. M., Letai, A. G., & Keating, A. E. (2014) · Journal of Molecular Biology · doi:10.1016/j.jmb.2014.09.030 · Cited by 41
Bates, D. J. P., Danilov, A. V., Lowrey, C. H., & Eastman, A. R. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-1197 · Cited by 39
“Gelsolin cleavage was used as a marker of platelet apoptosis (24, 25).”
Method
Metadata
- Authors
- Zhang, H., Nimmer, P. M., Tahir, S. K., Chen, J., Fryer, R. M., Hahn, K. R., Iciek, L. A., Morgan, S. J., Nasarre, M. C., Nelson, R., Preusser, L. C., Reinhart, G. A., Smith, M. L., Rosenberg, S. H., Elmore, S. W., & Tse, C.
- Affiliations
- Abbott (United States) (US)
- Corresponding author
- Elmore, S W
- Tse, C
- Venue
- Cell Death & Differentiation
- Published
- 2007-01-05
- Volume
- 14
- Issue
- 5
- Pages
- 943-951
- ISSN
- 1350-9047 (ISSN-L)
- 1476-5403
- OpenAlex
- W1976197588
- Cited by
- 427
- References
- 32
- Citations by year
- 2026: 12 · 2025: 16 · 2024: 17 · 2023: 20 · 2022: 28 · 2021: 38 · 2020: 31 · 2019: 15 · 2018: 24 · 2017: 27 · 2016: 27 · 2015: 23 · 2014: 27 · 2013: 26 · 2012: 21
- FWCI
- 11.29
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Cell Death and Differentiation (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Hematology › Platelet Disorders and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
- Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
- Keywords
- platelet survival, Bcl-2 family proteins, ABT-737, platelet clearance, caspase-3 activation, cytochrome c release, phosphatidylserine exposure, mitochondrial membrane potential, reticuloendothelial system, hepatic clearance, platelet activation, hemostasis
- MeSH terms
- Animals, Biphenyl Compounds, Blood Platelets, Cell Separation, Cell Survival, Cytoplasmic Granules, Dogs, Dose-Response Relationship, Drug, Exocytosis, Flow Cytometry, Humans, Liver, Male, Nitrophenols, Phosphatidylserines, Piperazines, Platelet Aggregation, Platelet Count, Sulfonamides, Apoptosis, Proto-Oncogene Proteins c-bcl-2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.